Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2025 Earnings Presentation
24 slides from Alkem Laboratories's earnings presentation, Feb 7, 2025
Slide 1: Exchange cover letter for press release and analyst presentation
07th February, 2025 To, The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Press Release and
Slide 2: Alkem reports Q3 & 9MFY25 results
Press Release Alkem reports Q3 & 9MFY25 results Mumbai, February 7, 2025: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the third quarter and nine months ended December 31, 2024. The Board of Directors took record of these results at its meeting held i
Slide 3: CEO commentary and operational highlights: domestic business
Commenting on the Q3FY25 results, Dr Vikas Gupta, CEO of Alkem, said, “We are pleased to share that the actions we have taken to improve profitability continue to deliver positive results. By concentrating on higher-margin offerings, better aligning with market needs, and implementing cost-saving st
Slide 4: Key performance highlights of therapeutic segments in Q3FY25 and 9MFY25
Key performance highlights of therapeutic segments in Q3FY25 and 9MFY25 Q3FY25 9MFY25 Alkem YoY change in YoY YoY Alkem YoY change in YoY YoY growth Key Therapy segment Rank Rank* growth growth Rank Rank* growth (Alkem) (IPM) (Alkem) (IPM) ANTI DIABETIC 14 Increase by 1 12.0% 9.1% 14 Increase by 1 1
Slide 5: Update on USFDA Inspections
Update on USFDA Inspections Facility Capability Inspection Date Regulatory Status Baddi (India) Formulations Mar-24 EIR Received in June 2024 Daman (India) Formulations Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Bioequivalence Centre Oct-22 No observation Ankleshwar (India) API Apr-23 EIR Re
Slide 6: Invite for Q3 & 9MFY25 Conference Call
Invite for Q3 & 9MFY25 Conference Call at 4 pm IST, February 07, 2025 Mumbai, February 07, 2025: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Friday, February 07, 2025, from 4:00 pm to 5:00 pm IST t
Slide 7: Investor Presentation Q3 & 9MFY25
Investor Presentation Q3 & 9MFY25 February 07, 2025
Slide 8: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 9: Key Highlights of Q3FY25
Key Highlights of Q3FY25 • Total Revenue from Operations was ₹ 33,743 million, with YoY growth of 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o The contribution of domestic sales to total sales in Q3FY25 was 71.1% vs. 68.6% in Q3FY24. o International sales were ₹ 9,605 millio
Slide 10: Key Financial Highlights – Q3FY25 (Consolidated)
Key Financial Highlights – Q3FY25 (Consolidated) All figures in ₹ Mn Total Revenue from Operations Domestic sales 23,649 22,328 33,239 33,743 Q3FY24 Q3FY25 International sales 10,240 9,605 Q3FY24 Q3FY25 Q3FY24 Q3FY25
Slide 11: Key Financial Highlights – Q3FY25 (Consolidated)
Key Financial Highlights – Q3FY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 7,076 7,594 20,193 21,700 60.8% 64.3% 21.3% 22.5% Q3FY24 Q3FY25 Q3FY24 Q3FY25 PBT (before exceptional item) PAT (after Minority Interest) 5,950 6,258 7,062 7,311 17.9% 18.5% Q3
Slide 12: India - Secondary Sales Performance
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in Q3FY25 1 3 3 2 8 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.2% 9.3% 7.4% 6.9% 7.5% 5.0% 5.4% 2.0% 2.1% 2.8% Alkem sales growth Y
Slide 13: US Business Update
US Business Update Q3FY25 Sales of ₹ 6,340 million (7.3% YoY de-growth) • Overall contribution of US sales to total sales was 19.1% in Q3FY25. • During the quarter, the Company has received two approvals from the USFDA, including one tentative approval. Q3FY25 – US Sales (₹ Mn) Q3FY25 – US Sales (₹
Slide 14: Other International Market Update
Other International Market Update Q3FY25 Sales of ₹ 3,265 million (4.0% YoY de-growth) • Other International Market sales contributed 9.8% to total sales in Q3FY25. • The Company has a presence mainly in Latin America, Australia and Europe. Q3FY25 – Other International Sales (₹ Mn) Q3FY25 – Other In
Slide 15: Key Highlights of 9MFY25
Key Highlights of 9MFY25 • Total Revenue from Operations was ₹ 98,208 million, with YoY growth of 0.9%. o India sales were ₹ 68,482 million, YoY growth of 6.0%. o The contribution of domestic sales to total sales in 9MFY25 was 70.6% vs. 67.6% in 9MFY24. o International sales were ₹ 28,463 million, w
Slide 16: Key Financial Highlights – 9MFY25 (Consolidated)
Key Financial Highlights – 9MFY25 (Consolidated) All figures in ₹ Mn Total Revenue from Operations Domestic sales 64,613 68,482 97,318 98,208 9MFY24 9MFY25 International sales 30,928 28,463 9MFY24 9MFY25 9MFY24 9MFY25
Slide 17: Key Financial Highlights – 9MFY25 (Consolidated)
Key Financial Highlights – 9MFY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 21,209 59,016 63,358 18,435 60.6% 64.5% 18.9% 21.6% 9MFY24 9MFY25 9MFY24 9MFY25 PBT (before exceptional item) PAT (after Minority Interest) 18,596 15,022 21,307 17,648 15.4% 18
Slide 18: India - Secondary Sales Performance
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in 9MFY25 1 3 3 2 8 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.6% 10.6% 9.6% 7.5% 7.9% 2.5% 5.2% 6.0% 5.3% 3.3% Alkem sales growth
Slide 19: US Business Update
US Business Update 9MFY25 Sales of ₹ 18,732 million (12.7% YoY de-growth) • Overall contribution of US sales to total sales was 19.3% in 9MFY25. • As of December 31, 2024, the Company had filed 179 ANDAs and 2 new drug applications (NDAs) with the USFDA. Of these, it had received approvals for 154 A
Slide 20: Update on USFDA inspections as of 31 Dec 24
Update on USFDA inspections as of 31 Dec 24 Facility Capability Inspection Date Regulatory Status Baddi (India) Formulations Mar-24 EIR Received in June 2024 Daman (India) Formulations Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Bioequivalence Centre Oct-22 No observation Ankleshwar (India) A
Slide 21: Other International Market Update
Other International Market Update 9MFY25 Sales of ₹ 9,731 million (2.9% YoY growth) • Other International Market sales contributed 10.0% to total sales in 9MFY25. • The Company has a presence mainly in Latin America, Australia and Europe. 9MFY25 – Other International Sales (₹ Mn) 9,459 9,731 9MFY24
Slide 22: Shareholding Pattern as on Dec 31, 2024
Shareholding Pattern as on Dec 31, 2024 Non-Institution BSE Ticker 539523 16.12% NSE Symbol ALKEM Promoter & Shares Outstanding (Mn) 120 Promoter Group MCap (Rs in Mn)* 673,868 Institution 55.66% 28.22% Free Float Mcap (Rs in Mn) 298,861 Industry Pharmaceuticals *Share Price - Rs 5,636 from NSE as o
Slide 23: Key Financial Highlights – Q3 & 9MFY25 (Consolidated)
Key Financial Highlights – Q3 & 9MFY25 (Consolidated) All figures in ₹ Mn Particulars Q3FY25 Q3FY24 YoY growth 9MFY25 9MFY24 YoY growth Revenue from Operations 33,743 33,239 1.5% 98,208 97,318 0.9% Gross Profit 21,700 20,193 7.5% 63,358 59,016 7.4% Gross Profit Margin 64.3% 60.8% 64.5% 60.6% EBITDA
Slide 24: Thank You
Thank You For any queries, contact: Purvi Shah Head of Investor Relations Mobile: +91 84337 00890 E-mail: purvi.shah@alkem.com Tel: +91 22 3982 9999 Ext: 9447